Products & Care

Depending on their needs, end customers can benefit from their own bricks-and-mortar pharmacies, home care services, mail-order pharmacies and online shops. Galenica also supports healthcare providers such as pharmacies, drugstores, physicians, care homes, hospitals and home care organisations as a strong partner.

“Products & Care” segment key figures

The “Products & Care” segment achieved net sales of CHF 1,816.4 million (+6.8%) in the 2025 financial year. Of this, CHF 1,473.3 million (+4.9% excluding Coop Vitality and Mediservice) was attributable to the “Pharmacies Omni-Channel” business area. The “Products & Brands” business area increased sales to CHF 194.2 million (+2.1%), while the “Services & Production” business area grew by 4.0% to CHF 119.9 million. The new “Diagnostics” business area contributed CHF 40.7 million to sales growth.

The adjusted¹⁾ operating result (EBIT) increased by 9.4% to CHF 175.2 million in the 2025 financial year, while the adjusted¹⁾ return on sales (ROS) also increased to 9.6% (previous year: 9.4%).

Investments in the “Products & Care” segment amounted to CHF 23.3 million (previous year: CHF 24.7 million) and were connected with pharmacy renovations in particular.

¹⁾ See definition in section “Alternative performance measures”.

Pharmacies Omni-Channel

Pharmacies in the Galenica network have further expanded their role as the first point of contact in the healthcare system. Galenica strengthened the pharmacy network by a net figure of 5 locations through targeted acquisitions, taking the total to 381 pharmacies (with Coop Vitality). Sales in the “Pharmacies Omni-Channel” sector increased by 4.9% to CHF 1,473.3 million (excluding Coop Vitality).

Adjusted for the expansion effect of 1.6%, the area grew organically by 3.3%, which is slightly above market growth for inpatient pharmacies taking the product mix into account (Rx and OTC products: 5.3%², non-drugs segment in the consumer healthcare market: -0.8%³).

²⁾ IQVIA, Pharmaceutical Market Switzerland, 2025
³⁾ IQVIA, Consumer Health Market Switzerland, 2025

Strengthening basic care and exploiting market potential

Pharmacies are the easiest way to access healthcare for many people in Switzerland: close to home, knowledgeable and effective. When experiencing acute symptoms, customers receive prompt, sound pharmaceutical assistance at pharmacies. In view of rising healthcare costs and a shortage of skilled workers, pharmacies are playing an increasingly important role in basic care. They deal with issues relating to health and well-being efficiently and take the strain off or complement the healthcare system where doing so makes sense. Politicians support this development: With cost containment package 2, Parliament expanded the remit of pharmacists in the reporting year and paved the way for certain services to be covered by compulsory health insurance in future.

With “Consultation plus”, Galenica is further advancing the status of pharmacies as the first point of contact for healthcare advice and is continuously expanding its healthcare services in a customer-oriented manner. To this end, the company has been making targeted investments in training, infrastructure, digital solutions and marketing communication for several years now. And the investments are bearing fruit: demand for fee-based consultations and healthcare services rose again year on year, increasing by around 29% to 368,000. “Consultation plus” will be available throughout the pharmacy network by the end of 2026.

Collaborations and partnerships boost demand for healthcare services

Demand for vaccinations is also steadily increasing. More and more cantons are allowing a broader range of vaccinations in pharmacies, and the number of vaccinations carried out rose to around 93,000 in 2025. Influenza, COVID and TBE vaccinations were once again the most in demand. Getting teams qualified in good time as part of the “Consultation plus” offering is now enabling Galenica to meet growing demand: more than 800 Galenica pharmacists have the necessary certificate of proficiency, meaning that almost all pharmacies can offer vaccinations. In addition, Galenica expanded its collaboration with companies in the year under review: more than 120 companies – from small businesses to large companies with over 10,000 employees – gave their workforce free flu vaccinations at a Galenica pharmacy. This resulted in almost 7,000 vaccinations.

“Consultation plus” has also opened doors for health insurers: thanks to standardised services throughout Switzerland, they are increasingly positioning our pharmacies as entry points for various basic and supplementary insurance models. Cooperations with health insurers are also helping to raise awareness of “Consultation plus” in the market. In recent years, Groupe Mutuel has attracted a significant number of additional customers with its PrimaFlex model. Galenica has also concluded two further strategically important collaborations with Helsana and KPT, which will take effect on 1 January 2026. From 2026, Galenica will therefore be working with six major health insurers as part of alternative insurance models, which will enable it to reach around one million people with health insurance.

Galenica tests new pharmacy concept

To make the central role of the pharmacy tangible in day-to-day life, Galenica developed a new concept that Amavita has been piloting at the Glatt shopping centre Zurich since October 2025. It contributes to further expanding consultation as a core task of pharmacies and offers a modern customer experience: private consultation areas create space for discreet conversations, self-check-out counters enable quick purchases, and digital services can be easily integrated into the consultation process. By combining digital and bricks-and-mortar services, Galenica is also strengthening the relevance of the pharmacy in an increasingly virtual healthcare world, where 80% of customers obtain information online before seeking advice. Further pilot pharmacies are planned for 2026; findings on customer behaviour, processes and training requirements will be take into account when refining the concept.

Digital services for a seamless customer journey

Galenica is expanding its pharmacy offering with digital services and improving the convenience and availability of its services across all channels. The Amavita and Sun Store online shops performed positively in 2025. Click & Collect orders grew significantly faster than the market at around 50%. With the increase in investment in Puravita, announced in December, we are now expanding our online offering in the drugstore segment and, in particular, in the over-the-counter range. Launched in early 2025, the Prescription Manager simplifies the management of prescriptions and medication orders. Customers can order medication and have it delivered to their home or a pharmacy of their choice. By the end of the year, more than 46,000 people were already using the new digital helper.

Online appointment booking via OneDoc is already well established: over 90% of Galenica pharmacies offer appointments for vaccinations and other healthcare services this platform. By the end of December 2025, almost 40% of all appointments for flu vaccinations had been booked via OneDoc – significantly more than in the previous year. Galenica also networks its offerings via the Well and Compassana health platforms, some of which are directly integrated into certain insurance models. As a partner of Well and ecosystem partner of Compassana since 2025, the services of Galenica pharmacies are available to insured people – for example, via the Symptom Checker.

Pharmacy network continues to grow

Galenica is strengthening its network in a strategic manner through acquisitions at attractive locations. In the reporting year, additional pharmacies were added, including in Lausanne, Biasca and Würenlos. Amavita not only celebrated its 20th anniversary in 2025, but also opened its 200th location. By the end of 2025, the network comprised 381 pharmacies. This corresponds to net growth of 5 pharmacies (9 acquisitions, 1 new opening, 5 restructurings). Further acquisitions took effect on 1 January 2026, including Apotheke Ryser AG, which supports and supplies numerous institutions in the Burgdorf region, and the acquisition of pharmacy pharmacieplus Salzmann in Malleray. Galenica is thus further expanding its reach in primary care and strengthening the basis for its range of services in both German-speaking and French-speaking Switzerland.

In the year under review, Galenica made targeted efforts to drive efficiency and culture in its pharmacies. The centrally managed pool of people on stand-by, for example, optimised resource planning and supported productivity as well as cost management. To ensure continuous progress, the pharmacies also applied lean methods to prioritise activities and implement improvements. Amavita’s 20th anniversary also fostered participation and collaboration: employees designed the programme themselves, thereby strengthening team spirit in the long term.

Winconcept reaches an important milestone for partner pharmacies

Winconcept supports the independent operations of the Feelgood’s pharmacy group with a wide range of services. In 2025, the company gained 30 new pharmacies as partners – 19 of them in German-speaking Switzerland, ten in French-speaking Switzerland and one in Ticino. This positive development was driven by an expanded offering with additional marketing, communications and healthcare services and systematic cultivation of relationships. As of 1 January 2026, the Winconcept team is supporting 202 partner pharmacies, surpassing the key threshold of 200 partner pharmacies.

Products & Brands

In the Swiss consumer healthcare market, Galenica further consolidated its leading position with sales growth of 6.2% to CHF 158.0 million. Sales growth is supported by Cooper Consumer Health products, for which Verfora has been responsible since 2025. One-time effects led to exceptionally high disposals in Switzerland and in the export business in the same period of the previous year. Export business declined accordingly by -12.6% to CHF 36.2 million in 2025.

Sales of Verfora products in the Swiss pharmacy and drugstore market decreased slightly by -0.6% due to low demand for cold and pain relief products. In the same period, the Swiss consumer healthcare market declined by -0.4%³, leaving Galenica slightly below market level due to the product mix.

³⁾ IQVIA, Consumer Health Market Switzerland, 2025

Verfora enjoys continued success in its brand development

Verfora successfully continued its strategy of expanding leading brands through targeted advertising investments and product range expansions in 2025. New product lines and innovations already launched in the fourth quarter of 2024 helped strengthen the core brands. At the same time, Verfora continued its growth by taking on distribution contracts, acquiring the Cooper Consumer Health portfolio and the SVR cosmetics brand in January 2025. Complementary medicine showed pleasing growth, driven in particular by the very strong development of the Omni-Biotic^® probiotic range. In terms of exports, the Southeast Asian markets for Perskindol^® continued to develop positively.

Services & Productions

The “Services & Production” sector also performed positively and grew by 4.0% to CHF 119.9 million. All units – Bichsel, Lifestage and Medifilm – contributed to this growth.

Together in the home care market

Galenica has specifically bundled its offerings in the home care sector. The digital platform Lifestage Solutions and HomeCare Bichsel have been operating on the market with a joint management structure since October 2025. The combined expertise creates a unique offering in the Swiss home care market: many years of experience in the provision of clinical nutrition and a digital platform for the automated ordering and billing of consumables. The standardisation of central systems will further strengthen integrated care and progressively ease the burden on nursing staff. Customers will continue to be approached via the two existing, well-established brands, Lifestage Solutions and Bichsel.

Blister packaging further expanded and strengthened

Medifilm remained an important growth driver in the year under review and further expanded its key role in the Galenica home care network. Following the capacity expansion in the previous year, the company put another fully integrated blister packaging machine into operation in 2025 and was already preparing to roll out a third system – an important step in meeting rising demand. The number of patient days once again increased significantly by 10%, underlining the persistently high demand for patient-specific blister packaging in care homes, home care organisations and pharmacies. Medifilm works closely with the entire Galenica home care organisation; machine blister packaging is a key performance element in market development.

Diagnostics

With the acquisition of Labor Team, Galenica was able to further develop its healthcare network in September and expand it with the “Diagnostics” area. With sales of CHF 40.7 million in 2025, Labor Team contributed around 1% to the Group’s sales growth.

Strategic expansion of the healthcare network through the Labor Team

Labor Team is the fourth largest private medical laboratory in Switzerland with a market share of around 8%. The company has approx. 350 employees and covers a wide range of services, ranging from laboratory medicine and pathology to personalised special diagnostics. In Goldach, it operates the largest central laboratory in Switzerland, supplemented by several speciality laboratories and an efficient logistics network.

Labor Team is managed by physicians and stands out on the market due to its high level of innovation and efficient, largely automated processes. In addition, the diagnostics service provider is the only laboratory in Switzerland to be certified as a “Green & Sustainable Laboratory” by the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM). The company is further distinguished by its environmentally friendly transport concept that focuses primarily on bicycle couriers and rail, contributing to Galenica’s sustainable development goals.

Strategically, the business activities of Labor Team and Galenica are the perfect complement for each other. Together, both companies can add value within the network: Galenica can offer its customers innovative laboratory services and further expand its offerings in the medical market, while Labor Team has access to additional customer groups.